The Insurance Sector Playbook

First published 23 Aug 2026 · Last verified 29 Aug 2026

Lesson 74.1 — Two Businesses Wearing One Sector Label

Rukmani Thapa had made good money in microfinance shares, and she assumed insurance would work the same way. Both sectors, after all, sat under the same regulatory umbrella of forced consolidation, both had been pushed through capital hikes, and both showed up on her screener with double-digit return on equity in good years. In late 2021 she bought into three insurers in a single week — one life, one non-life, one that had just announced a merger — using the same checklist she used for microfinance. Eighteen months later, one of the three had cut its dividend to nothing after a single bad monsoon season of motor and crop claims, one had quietly diluted her position through a rights issue she hadn't budgeted for, and only the life insurer had compounded the way she expected. When she went back to find out why, she discovered she had never actually understood what she owned. A microfinance company lends money and earns a spread. An insurer sells a promise, invests the premium while the promise is outstanding, and only finds out years later — sometimes decades later, in the case of a life policy — whether the promise cost more than the premium collected. That difference in timing is the entire chapter.

Insurance is the only sector on the NEPSE board where the product being sold is a bet on the future, priced today, paid out later, and where the shareholder's return depends less on this quarter's premium collections than on how conservatively the company reserved against claims nobody has filed yet. It is also, not coincidentally, the sector most recently forced through the same regulator-driven capital consolidation that reshaped banking and microfinance — except compressed into a shorter window and layered on top of a mandatory reinsurance regime that no other NEPSE sector has to deal with. Getting this chapter right means holding two separate business models in your head at once, because a life insurer and a non-life insurer are answering completely different questions with completely different accounting, even though both trade under the same "Insurance" sector tag on your broker's screen.

Start by separating what most Nepali retail investors lump together. Life insurance and non-life (general) insurance are licensed separately by the Nepal Insurance Authority, cannot be written by the same company, and behave like different asset classes entirely. A life insurer sells long-duration contracts — endowment, term, and increasingly unit-linked-style products — where premiums are collected for years or decades before a death, maturity, or surrender triggers a payout. A non-life insurer sells short-duration contracts — motor, fire, marine, engineering, crop, health — where the policy period is typically twelve months and claims, when they occur, are usually settled within one to two years of the loss event. That single difference in duration changes everything downstream: how each recognises profit, what its balance sheet looks like, what breaks it, and what a rational shareholder should actually be underwriting when buying the stock.

A non-life insurer's economics resemble a fast-turning inventory business. It collects a premium, sets aside a reserve for expected claims and unearned premium, and the difference between the two — adjusted for expenses and reinsurance — is roughly the underwriting result for the year. Because the float period is short, a non-life insurer's profitability is visible relatively quickly: a bad year of claims (a widespread hailstorm damaging standing crops, a flood season generating a spike in motor and property claims, a fire loss in an industrial client) shows up in that same year's combined ratio and that same year's profit. This is why non-life insurance profit is lumpier and more cyclical than life insurance profit — it is closer to a P&L business than a balance-sheet business, even though the balance sheet still matters enormously for solvency.

A life insurer's economics resemble a long-duration bond fund with a mortality overlay. Premiums collected today are not "earned" the way a non-life premium is earned over twelve months; instead, a portion goes toward the current year's mortality and expense cost, and a much larger portion is set aside in actuarial reserves that will, on average, be needed to pay the policy's eventual maturity or death benefit — which for many endowment products is ten, fifteen, or twenty years away. The insurer invests this accumulating reserve pool, and the spread between what it earns on that invested float and what it has actuarially promised policyholders is a major source of shareholder profit, realised gradually over the life of the book rather than in the year premiums are collected. This is why a life insurer's single-year net profit is a much noisier signal of true economic value creation than a non-life insurer's — a life insurer can show a soft profit in a year when its underlying book of business actually got healthier (higher persistency, better mortality experience, growing embedded value) simply because actuarial reserving conventions defer recognition.

Rukmani's mistake in 2021 was treating all three of her insurance holdings as one homogeneous "insurance sector" bet. The non-life insurer she bought was exposed to a bad monsoon; the life insurer she bought was exposed to persistency and interest-rate assumptions on its reserves; the merging insurer she bought was exposed to integration risk and dilution. None of those risks correlate with each other in the way, say, two commercial banks' credit cycles correlate. Sector-level diversification within insurance is close to meaningless unless you know which sub-model each holding actually runs.

Lesson 74.2 — The Metrics That Actually Matter: Non-Life Insurance

For a non-life insurer, the single most important number is the combined ratio — the sum of the claims ratio (net claims incurred divided by net premium earned) and the expense ratio (management and commission expenses divided by net premium earned). A combined ratio below 100 percent means the company is making an underwriting profit before investment income; above 100 percent means the company is losing money on the insurance business itself and depends entirely on investment income to stay profitable. Nepali non-life insurers routinely disclose figures close to or occasionally over 100 percent, which is not automatically alarming — many mature non-life insurers globally run combined ratios in the high 90s to low 100s and still compound shareholder value because of investment income on the float — but a combined ratio that is deteriorating year over year, especially driven by the claims ratio rather than the expense ratio, is the first place to look for trouble.

The claims ratio in isolation tells you about underwriting discipline and pricing power. A rising claims ratio can mean genuine adverse experience (a bad monsoon, a spike in motor accidents, an unusually large single fire or engineering loss) or it can mean the company has been underpricing risk to win market share, which is a much more structural problem. Because Nepal's non-life market has historically been intensely competitive on price — with more than a dozen listed non-life insurers chasing a motor and fire book that does not grow fast enough to absorb all of them profitably — chronic claims-ratio deterioration across the sector, not just at one company, has been a recurring concern flagged by both the regulator and industry commentators pushing for consolidation.

The solvency margin ratio is the second pillar, and it is a regulatory survival metric rather than a profitability metric. The Nepal Insurance Authority (NIA) requires every insurer, life and non-life, to maintain available solvency capital at a multiple of its required solvency margin — historically set around 1.5 times under the older Solvency Margin Directives (2070 for life insurers and 2071 for general insurers), with the NIA subsequently moving the framework onto a more risk-sensitive footing through the Risk-Based Capital and Solvency Directive first issued in 2078/2081 and refined further in 2082. Under this newer framework, capital requirements are calibrated more granularly to the actual risk profile of each insurer's book — mortality risk, catastrophe risk, investment risk, concentration risk — rather than a flat multiple applied uniformly. Reported solvency ratios in the Nepali non-life market have generally run well above the regulatory floor, with sector averages reported north of 2.5 times required capital in recent NIA disclosures reviewed by industry trade press, and life insurers showing a similar pattern of comfortable headroom in aggregate. A comfortable sector average does not mean every individual company is comfortable, however, and the solvency ratio is precisely the number to check company-by-company before assuming any listed insurer is safe.

Investment income contribution to profit is the third number every non-life investor should isolate. Because non-life insurers hold sizeable investment portfolios funded by policyholder float (unearned premium reserves plus claims reserves), a meaningful share of reported net profit in most listed Nepali non-life insurers comes not from underwriting but from interest income, dividend income, and gains on their fixed deposit and government security holdings. In years when the combined ratio deteriorates, a strong investment book can mask the underlying underwriting weakness in the headline profit number — which is exactly why Rukmani's non-life holding kept paying a dividend for two years after its claims ratio had already started climbing, until a genuinely bad claims year finally overwhelmed the investment cushion and the dividend was cut. Always ask what fraction of net profit is underwriting result versus investment result, and never assume investment income growth alone signals a healthier insurance franchise.

Lesson 74.3 — The Metrics That Actually Matter: Life Insurance

Life insurance metrics revolve around persistency, reserve adequacy, and the concept of embedded value, all of which exist to answer one underlying question: is the book of business the company has written actually going to deliver the profit its pricing assumed, or is it going to lapse, underperform, or cost more than reserved?

The persistency ratio measures the proportion of policies (by premium or by count) that remain in force and continue paying renewal premiums after the first year, and typically after subsequent years as well. A first-year persistency ratio in the 80s (percent) is generally considered healthy for the Nepali market; a ratio sliding into the 60s or lower signals that a large share of new business is lapsing before it ever becomes profitable, because life insurance products are typically front-loaded with acquisition costs — agent commissions, medical underwriting, policy issuance expenses — that are only recovered over several years of renewal premiums. A life insurer that grows new business aggressively but cannot retain policyholders past year one or two is manufacturing an accounting profit today (the first premium) while quietly destroying economic value, because the cost of acquiring that policy will never be recouped. This is arguably the single most important number in life insurance analysis and the one most likely to be glossed over in headline results, because persistency does not appear in the income statement — it has to be pulled from actuarial disclosures, annual report notes, or NIA aggregate data.

Reserve adequacy is harder for a retail investor to independently verify because it depends on actuarial assumptions — mortality tables, lapse assumptions, discount rates — that are not fully disclosed in NEPSE-level annual reports the way they would be in a market with mandated embedded value reporting. What you can do is watch the trend: is the actuarial reserve per unit of sum assured rising in a way that outpaces premium growth (a sign the appointed actuary is toughening assumptions, often after adverse experience), and has the auditor or actuary flagged any reserving strengthening in the notes to accounts. A sudden jump in reserves relative to premium income, absent a corresponding jump in business volume, is usually the actuary catching up to bad news rather than a one-off accounting choice.

Embedded value — the present value of future profits expected from the existing in-force book, plus adjusted net asset value — is the metric international life insurance investors use to value a life insurer properly, because a single year's IFRS-style or Nepal GAAP-style net profit dramatically understates the value being created in a growing life book (since most of the profit is deferred into future years' reserve releases). Nepali listed life insurers do not, as a rule, publish formal embedded value statements the way listed insurers in more developed markets like India do, which is a structural disclosure gap investors should be aware of rather than assume away. In the absence of published embedded value, a reasonable proxy is to track the growth in total actuarial liabilities (a rough proxy for the size of the in-force book) alongside the trend in persistency and claims experience, understanding that you are working with an approximation, not a true embedded value calculation. Investors who want a genuine handle on economic value in a Nepali life insurer should treat this as an acknowledged blind spot, size their position accordingly, and lean more heavily on persistency, solvency, and dividend-paying consistency as the observable proxies for underlying book quality.

Lesson 74.4 — The Nepal Insurance Authority: Solvency, Section 43, and Mandatory Reinsurance

Nepal's insurance regulator was reconstituted from the earlier Insurance Board (Beema Samiti) into the Nepal Insurance Authority (NIA) under the Insurance Act 2079, giving it a broader risk-based supervisory mandate closer to how Nepal Rastra Bank supervises banks and how SEBON supervises capital markets. Three planks of NIA regulation matter most to a NEPSE insurance investor: solvency requirements, dividend conditions, and mandatory reinsurance.

On solvency, the direction of travel has been from a flat solvency-multiple requirement toward a full risk-based capital regime. The Risk-Based Capital and Solvency Directive, first brought into force in 2078/2081 and updated again in 2082, requires insurers to hold capital calibrated against the specific risks on their books — underwriting risk, market and investment risk, credit risk, operational risk — rather than a single uniform multiplier applied identically to a conservative motor-only insurer and an aggressive insurer with concentrated catastrophe exposure. This is a meaningfully more sophisticated framework than the older 1.5-times solvency-margin directives it replaces, and it means two insurers with an identical headline solvency ratio today can have very different real cushions once their specific risk composition is properly risk-weighted. For a retail investor this mostly manifests as a number in the quarterly disclosure — check that it is comfortably above 1.0 (the barest regulatory floor under risk-based capital) and ideally well above the levels the company itself has historically run at, since a ratio that has compressed sharply quarter over quarter, even while remaining technically compliant, is an early signal the company is either growing capital-intensive business faster than it is retaining earnings, or absorbing losses that are eating into its cushion.

On dividends, Chapter 68 already covered Section 43 of the Insurance Act in detail as it applies across the sector — the requirement that an insurer can only distribute dividends out of net profit after making full actuarial and technical provisions, meeting minimum solvency and capital adequacy thresholds, and setting aside required reserves, with the NIA empowered to restrict or disallow a dividend if these conditions are not met regardless of the accounting profit shown. The practical consequence for insurance-sector investors specifically is that a headline net profit figure at a Nepali insurer is not itself sufficient evidence a dividend is coming; the solvency test sits on top of the profit test, and an insurer that is profitable on paper but running a thin solvency cushion can be blocked from distributing regardless of what the income statement says. Cross-reference the solvency ratio against the dividend history before assuming continuity.

Mandatory reinsurance is the plank that has no equivalent anywhere else on the NEPSE board, and it is worth understanding in some detail because it directly affects both an insurer's risk profile and its profit and loss statement. Nepal Reinsurance Company Limited (Nepal Re) was established as the country's first and, for years, only domestic reinsurer, and NIA regulation has required Nepali primary insurers — both life and non-life — to cede a defined percentage of their gross premium to Nepal Re before placing any remaining reinsurance need with foreign reinsurers. This mandatory cession requirement has moved over time: it was scaled back for a period as authorities weighed concerns about risk concentration in a single domestic reinsurer against the policy goal of retaining reinsurance premium (and the foreign-exchange outflow it represents) inside Nepal, and industry reporting in 2026 pointed to the government reinstating a mandatory cession requirement around 20 percent of ceded business to Nepal Re. The precise percentage has shifted with policy cycles, so any investor underwriting a primary insurer's reinsurance cost line should check the currently applicable NIA directive rather than assume a fixed historical number, but the structural point holds regardless of the exact percentage in force: a chunk of every Nepali insurer's reinsurance program is not competitively priced in the open global market, it is placed with a single domestic counterparty whose own capital strength and claims-paying ability then becomes an indirect risk factor for every primary insurer that cedes to it.

This is why a genuinely thorough evaluation of any NEPSE-listed insurer includes at least a glance at Nepal Re's own capital adequacy and claims-paying trend, not just the primary insurer's numbers — the mandatory cession structure means primary insurers cannot simply shop around for a stronger reinsurance counterparty the way insurers in most other markets can if they judge their reinsurer's balance sheet to be weakening.

Lesson 74.5 — The Consolidation Wave: Why Insurance M&A Rhymes with Banking and Microfinance

Nepali investors who lived through the banking sector's forced-merger era (Chapter 30) and the microfinance consolidation covered in Chapter 73 will recognise the pattern immediately in insurance, because the regulatory logic is identical: a regulator decides the sector has too many undercapitalized, sub-scale players competing destructively for a limited pool of business, and forces consolidation by raising minimum paid-up capital requirements faster than most existing companies can organically build capital, leaving merger or acquisition as the only realistic path to compliance for a large share of the industry.

The insurance version of this played out concretely when the then-regulator required life insurance companies to raise minimum paid-up capital to roughly Rs 5 arba (Rs 5 billion) and non-life insurance companies to roughly Rs 2.5 arba (Rs 2.5 billion), with the compliance deadline extended more than once — reporting from 2023 referenced the deadline being pushed out to Ashad 2080 (mid-2023) — as regulators acknowledged how difficult a genuinely organic capital raise of that size was for smaller listed insurers to execute purely through rights issues and retained earnings. Several life insurers that could not credibly reach the new capital floor alone chose merger instead: the merger of Prime Life Insurance, Gurans Life Insurance, and Union Life Insurance into a single combined entity, which took the name Himalayan Life Insurance, is one of the clearest examples of this dynamic in the listed market, and it followed the same negotiated-swap-ratio, shareholder-approval, NIA-clearance process that Chapters 71 through 73 described for bank and microfinance mergers. Reinsurance-side capital requirements followed the same script one step further up the value chain, with the NIA separately mandating a large capital increase for reinsurance companies themselves, again with phased deadlines extended as the sector adjusted.

The investment implication is the same one that applied to microfinance in Chapter 73: consolidation is generally a medium-term positive for the sector — fewer, better-capitalised players competing less destructively on price should eventually improve combined ratios and persistency-driving service quality across the board — but it is frequently a short-term negative for individual shareholders caught inside a specific merger, because swap ratios are negotiated between boards and often undervalue the smaller or weaker party's minority shareholders relative to a clean market-price benchmark, dividend policy typically pauses during the NIA clearance process, and the combined entity needs one to two years to integrate distribution networks, actuarial reserving practices, and claims-processing systems before the promised efficiency gains show up in reported numbers. An investor holding an insurer that announces a merger should treat the announcement as the start of a waiting period, not a catalyst for an immediate re-rating, and should specifically model the swap ratio against the pre-announcement market price of both entities before assuming the deal is neutral or favourable.

The regulatory logic pushing this consolidation is unlikely to be finished. Nepal's insurance market — both life and non-life — still carries more listed underwriters than the size of the economy's insurable base comfortably supports at healthy combined ratios and persistency levels, and the NIA's move toward risk-based capital (which by design penalises thin, undiversified, or concentrated books more than the old flat-multiple regime did) creates ongoing pressure on the weakest capitalised players to either raise fresh equity, merge, or shrink their underwriting appetite. Investors should expect further rounds of NIA-driven capital tightening and consequent M&A activity across both life and non-life sub-sectors over the coming years, exactly as Chapter 73 anticipated for microfinance.

Lesson 74.6 — Float Management and the Practical Insurance Stock Checklist

Underneath both business models sits one shared truth: an insurer is, in large part, an investment management company that happens to sell insurance to generate the float it invests. The quality of that investment portfolio — its asset allocation across government securities, bank fixed deposits, corporate debentures, and listed equities, its duration matching against the liability profile, and its concentration risk in any single counterparty — drives a substantial share of both life and non-life profitability over a full cycle, and it is one of the more overlooked lines in Nepali insurance analysis because retail investors tend to focus almost exclusively on the underwriting metrics.

For a non-life insurer, float is short-duration by nature (claims and unearned premium reserves turn over within roughly a year or two), so the investment book tends to be weighted toward liquid, shorter-tenor instruments — fixed deposits and treasury bills — with a smaller allocation to listed equities and mutual funds for yield enhancement. For a life insurer, float is genuinely long-duration, so a well-run life insurer should be laddering into longer-tenor government securities and corporate debentures that roughly match the duration of its actuarial liabilities; a life insurer whose investment book is disproportionately parked in short-term fixed deposits despite carrying twenty-year policy liabilities is running a reinvestment-rate risk that will only become visible when interest rates fall and the company has to reinvest maturing deposits at a lower yield than its policies were priced to assume. Rukmani found, on digging into her life insurer's investment disclosures after her initial misstep, that its book was reasonably well laddered across government bonds and long-tenor debentures — one reason, she concluded, that it had kept compounding through the same period her mispriced non-life holding stumbled.

Bringing all of this together, here is a practical step-by-step checklist for evaluating any NEPSE-listed insurance stock, life or non-life: